Patient professional reference
Cytotoxic antibiotics are used very commonly and widely in many malignancies.
Method of action
Direct toxic action on cellular DNA.
- Solid tumours, eg bladder, gastric, pancreatic and oesophageal.
- Acute leukaemias.
- Breast cancer.
- Ovarian cancer - doxorubicin (see National Institute for Health and Clinical Excellence (NICE) guidance).
- Metastatic germ cell tumours and non-Hodgkin's lymphoma - bleomycin.
Important interactions and cautions
- Radiotherapy - some cytotoxic antibiotics can result in toxicity.
- Irreversible cardiotoxicity - must be used cautiously in patients with previous cardiac illness. (A liposomal formulation of doxorubicin is available which is associated with less cardiotoxicity.)
- Liver impairment.
- Skin reactions - especially with doxorubicin.
- Myelosuppression - usually occurs at 2-4 weeks with complete recovery by eight weeks. Rare with bleomycin, whereas mitomycin is associated with delayed myelosuppression.
- Extravasation causes severe skin necrosis.
- Excreted in bile; therefore, it is necessary to monitor bilirubin levels - if high, dose reduction is needed.
- Associated with cardiac toxicity - this is rare and includes supraventricular tachycardia (SVT) and cardiomyopathies (related to dose).
Further reading and references
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan; NICE Technology Appraisal, 2005
Safra T; Cardiac safety of liposomal anthracyclines. Oncologist. 2003
Rang HP, Dale MM, Ritter JM and Moore PK. (2003) Pharmacology, 5th ed, Bath, Churchill Livingstone
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.